A5102806985- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- Meningioma and schwannoma management
- Cancer-related Molecular Pathways
- MRI in cancer diagnosis
- Bone Tumor Diagnosis and Treatments
- Alzheimer's disease research and treatments
- Cell death mechanisms and regulation
- Advanced Neuroimaging Techniques and Applications
- Cholesterol and Lipid Metabolism
- Cancer, Lipids, and Metabolism
- Cell Adhesion Molecules Research
- Management of metastatic bone disease
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Angiogenesis and VEGF in Cancer
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cancer Genomics and Diagnostics
- Bone and Joint Diseases
- Intracerebral and Subarachnoid Hemorrhage Research
- Dementia and Cognitive Impairment Research
- Infrared Thermography in Medicine
- Head and Neck Surgical Oncology
Second Affiliated Hospital of Harbin Medical University
2024
Harbin Medical University
2024
University of California, Irvine
2022
University of California, Los Angeles
2012-2015
United States Nuclear Regulatory Commission
2012
University of Science and Technology of China
2008
Cedars-Sinai Medical Center
2002
<h3>BACKGROUND AND PURPOSE:</h3> Both <i>IDH1</i> mutation and <i>MGMT</i> promoter methylation are associated with longer survival. We investigated the ability of imaging correlates to serve as noninvasive biomarkers for these molecularly defined GBM subtypes. <h3>MATERIALS METHODS:</h3> MR from 202 patients was retrospectively assessed nonenhancing tumor edema among other features. mutational status were determined by DNA sequencing methylation-specific PCR, respectively. Overall survival...
<h3>BACKGROUND AND PURPOSE:</h3> A subset of patients with malignant glioma develops conspicuous lesions characterized by persistent restricted diffusion during treatment bevacizumab. The purpose the current study was to characterize evolution these and determine their relationship patient outcome. <h3>MATERIALS METHODS:</h3> Twenty restricted-diffusion undergoing bevacizumab were included in study. Mean ADC volume computed for each serial follow-up. Differences TTP, TTS, OS compared between...
Abstract Melatonin (MLT), a conserved small indole compound, exhibits anti‐inflammatory and antioxidant properties, contributing to its cardioprotective effects. Lipoprotein‐associated phospholipase A2 (Lp‐PLA2) is associated with atherosclerosis disease risk, known as an risk biomarker. This study aimed investigate the impact of MLT on Lp‐PLA2 expression in atherosclerotic process explore underlying mechanisms involved. In vivo, ApoE −/− mice were fed high‐fat diet, or without...
<h3>BACKGROUND AND PURPOSE:</h3> ADC histogram analysis can stratify outcomes in patients with GBM treated bevacizumab. Therefore, we compared gene expression between high-versus-low tumors to identify modules that could underlie this difference and impact patient prognosis. <h3>MATERIALS METHODS:</h3> Up-front bevacizumab-treated (<i>N</i> = 38) newly diagnosed glioblastoma were analyzed by using an approach based on enhancing tumor. Using microarrays, subsequently Tissue sections from a...
The arginine 132 (R132) mutation of isocitrate dehydrogenase -1 (IDH1(R132)) results in production 2-hydroxyglutarate (2-HG) and is associated with a better prognosis compared wild-type (WT) glioma patients. majority lower-grade gliomas express IDH1(R132), whereas this rare grade IV gliomas. aim study was to noninvasively investigate metabolic physiologic changes the IDH1 mouse model. Using 7T magnet, we MRI proton magnetic resonance spectroscopy (MRS) U87 cells overexpressing either mutated...
• Clinical, radiological, and immunohistochemical findings in brain biopsy specimens from six patients with cerebral amyloid angiopathy—associated intracerebral hemorrhage were reviewed. Acute clinical presentations included headache, nausea vomiting, loss of consciousness, focal neurological deficits such as hemiplegia blindness. Transient schemic attacks experienced by one patient referable to hemisphere did not indicate impending that region. Computed tomographic scans revealed acute,...
2016 Background: EGFR amplification in GBMs is a common occurrence and associated with treatment resistance. Erlotinib, selective inhibitor of EGFR, was combined TMZ RT phase II trial for GBMs. Methods: Adult patients not taking enzyme-inducing anticonvulsants after resection or biopsy GBM were treated erlotinib (150 mg daily) throughout the protocol until progression. Erlotinib alone delivered 1 week, then concurrent (75 mg/m2 (60 Gy), followed by up to 6 cycles adjuvant (200 mg/m2, daily x...
Abstract Introduction/Objective Aging adults with Down syndrome (DS) develop Alzheimer disease neuropathology (AD) by the age of 40 years, primarily due to overexpression amyloid precursor protein on chromosome 21. Lewy bodies (LBs), containing alpha-synuclein protein, are observed in 7-60% AD patients amygdala and cortex. Prior DS studies (n=20-56 cases) find frequency LB pathology range between 8-50% cases being affected. We hypothesized that would also be present brain similar locations...
2003 Background: The standard of care for patients with newly-diagnosed glioblastoma (GBM) consists postoperative radiotherapy and temozolomide (TMZ). O6-methylguanine-DNA methyltransferase (MGMT) provides resistance to TMZ, MGMT promoter methylation correlates improved treatment outcome presumably through silencing protein expression. However, the prognostic significance expression as assessed by immunohistochemistry (IHC) its relationship remain unclear. Methods: We identified 418 GBM...
Latino Americans are a rapidly growing ethnic group in the United States. The characteristics of glioblastoma this population is poorly studied. We have evaluated data 47,540 patients from Surveillance, Epidemiology, and End Results (SEER) Program National Cancer Institute. This SEER 1973-2000 includes up to 13 cancer registries. For 2001 2011, has improved geographic coverage with 18 registries encompassing 28% U.S. population. Latinos lower incidence GBM than non-Latino Whites. Gender...